These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

767 related articles for article (PubMed ID: 12210406)

  • 1. Factors associated with viral breakthrough in lamivudine monoprophylaxis of hepatitis B virus recurrence after liver transplantation.
    Chan HL; Chui AK; Lau WY; Chan FK; Wong ML; Tse CH; Rao AR; Wong J; Sung JJ
    J Med Virol; 2002 Oct; 68(2):182-7. PubMed ID: 12210406
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Outcome of lamivudine resistant hepatitis B virus mutant post-liver transplantation on lamivudine monoprophylaxis.
    Chan HL; Chui AK; Lau WY; Chan FK; Hui AY; Rao AR; Wong J; Lai EC; Sung JJ
    Clin Transplant; 2004 Jun; 18(3):295-300. PubMed ID: 15142051
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Post-transplant prophylaxis of the recurrence of lamivudine-resistant YMDD mutant hepatitis B virus in liver recipients].
    Yang Y; Yang Y; Zhang J; Yi HM; Lu MQ; Cai CJ; Li X; Jiang N; Xu C; Li H; Wang GS; Yi SH; Zhang JF; Jiang H; Yang Q; Chen GH
    Nan Fang Yi Ke Da Xue Xue Bao; 2008 Oct; 28(10):1810-2. PubMed ID: 18971179
    [TBL] [Abstract][Full Text] [Related]  

  • 4. No hepatitis recurrence using combination prophylaxis in HBV-positive liver transplant recipients with YMDD mutants.
    Caccamo L; Romeo R; Rossi G; Maggioni M; Radice F; Lunghi G; Colombo M; Fassati LR
    Transpl Int; 2005 Feb; 18(2):186-92. PubMed ID: 15691271
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of lamivudine in patients with hepatitis B virus precore mutant infection before and after liver transplantation.
    Ben-Ari Z; Zemel R; Kazetsker A; Fraser G; Tur-Kaspa R
    Am J Gastroenterol; 1999 Mar; 94(3):663-7. PubMed ID: 10086648
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild type after cessation of therapy.
    Chayama K; Suzuki Y; Kobayashi M; Kobayashi M; Tsubota A; Hashimoto M; Miyano Y; Koike H; Kobayashi M; Koida I; Arase Y; Saitoh S; Murashima N; Ikeda K; Kumada H
    Hepatology; 1998 Jun; 27(6):1711-6. PubMed ID: 9620347
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Residual hepatitis B virus particles in liver transplant recipients receiving lamivudine: PCR quantitation of HBV DNA and ELISA of preS1 antigen.
    Petit MA; Buffello-Le Guillou D; Roche B; Dussaix E; Duclos-Vallée JC; Féray C; Samuel D
    J Med Virol; 2001 Nov; 65(3):493-504. PubMed ID: 11596084
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genotypic resistance of hepatitis B virus to lamivudine in renal transplant recipients.
    Joh JW; Lee HH; Park JW; Lee DH; Yoo BC; Lee KW; Kim SJ
    Transplant Proc; 2005 Mar; 37(2):1235-7. PubMed ID: 15848680
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical and virological features of non-breakthrough and severe exacerbation due to lamivudine-resistant hepatitis B virus mutants.
    Suzuki F; Akuta N; Suzuki Y; Sezaki H; Arase Y; Hosaka T; Someya T; Kobayashi M; Saitoh S; Ikeda K; Kobayashi M; Matsuda M; Satoh J; Watahiki S; Kumada H
    J Med Virol; 2006 Mar; 78(3):341-52. PubMed ID: 16419116
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HBV-DNA suppression and disease course in HBV cirrhosis patients on long-term lamivudine therapy.
    Di Marco V; Di Stefano R; Ferraro D; Almasio PL; Bonura C; Giglio M; Parisi P; Cappello M; Alaimo G; Craxì A
    Antivir Ther; 2005; 10(3):431-9. PubMed ID: 15918334
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genotypic and phenotypic resistance: longitudinal and sequential analysis of hepatitis B virus polymerase mutations in patients with lamivudine resistance after liver transplantation.
    Ben-Ari Z; Daudi N; Klein A; Sulkes J; Papo O; Mor E; Samra Z; Gadba R; Shouval D; Tur-Kaspa R
    Am J Gastroenterol; 2003 Jan; 98(1):151-9. PubMed ID: 12526951
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A multicenter study of lamivudine treatment in 33 patients with hepatitis B after liver transplantation.
    Fontana RJ; Hann HW; Wright T; Everson G; Baker A; Schiff ER; Riely C; Anschuetz G; Riker-Hopkins M; Brown N;
    Liver Transpl; 2001 Jun; 7(6):504-10. PubMed ID: 11443577
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy.
    Yuen MF; Sablon E; Hui CK; Yuan HJ; Decraemer H; Lai CL
    Hepatology; 2001 Oct; 34(4 Pt 1):785-91. PubMed ID: 11584376
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lamivudine prophylaxis of liver allograft HBV reinfection in HBV related cirrhotic patients after liver transplantation.
    Lu SC; Yan LN; Li B; Wen TF; Zhao JC; Cheng NS; Liu C; Liu J; Wang XB; Li XD; Qin S; Zhao LS; Lei BJ; Zhang XH
    Hepatobiliary Pancreat Dis Int; 2004 Feb; 3(1):26-32. PubMed ID: 14969833
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differences of YMDD mutational patterns, precore/core promoter mutations, serum HBV DNA levels in lamivudine-resistant hepatitis B genotypes B and C.
    Pan XP; Li LJ; Du WB; Li MW; Cao HC; Sheng JF
    J Viral Hepat; 2007 Nov; 14(11):767-74. PubMed ID: 17927612
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The clinical impact of early detection of the YMDD mutant on the outcomes of long-term lamivudine therapy in patients with chronic hepatitis B.
    Paik YH; Han KH; Hong SP; Lee HW; Lee KS; Kim SO; Shin JE; Ahn SH; Chon CY; Moon YM
    Antivir Ther; 2006; 11(4):447-55. PubMed ID: 16856618
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The incidence and clinical outcome of YMDD mutants in hepatitis B surface antigen-positive renal allograft recipients after prolonged lamivudine therapy.
    Gwak GY; Huh W; Lee DH; Choi MS; Lee JH; Koh KC; Kim SJ; Joh JW; Oh HY
    Transplant Proc; 2007 Dec; 39(10):3121-6. PubMed ID: 18089336
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term experience with lamivudine therapy for hepatitis B virus infection after liver transplantation.
    Ben-Ari Z; Mor E; Shapira Z; Tur-Kaspa R
    Liver Transpl; 2001 Feb; 7(2):113-7. PubMed ID: 11172394
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Occurrence and predictive factors of hepatitis B virus polymerase YMDD variation among patients with chronic hepatitis B and liver cirrhosis during lamivudine therapy].
    Wang L; Yan J; Zhang ZH; Wang JB; Du YZ; Li XY; Wang YZ
    Zhonghua Gan Zang Bing Za Zhi; 2004 Oct; 12(10):585-8. PubMed ID: 15504286
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutational patterns of hepatitis B virus genome and clinical outcomes after emergence of drug-resistant variants during lamivudine therapy: analyses of the polymerase gene and full-length sequences.
    Enomoto M; Tamori A; Kohmoto MT; Morikawa H; Habu D; Sakaguchi H; Takeda T; Seki S; Kawada N; Shiomi S; Nishiguchi S
    J Med Virol; 2007 Nov; 79(11):1664-70. PubMed ID: 17854034
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 39.